Avenue Therapeutics Inc. (ATXI) Financials
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 ~1.5:1 split | DEC 2024 ~6.2:1 split | DEC 2023 ~11.7:1 split | DEC 2022 2:1 split | DEC 2021 |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $1 | $1 | $0 | — | — | — |
| General & Administrative | $3 | $4 | $5 | $4 | $5 | $2 |
| Research & Development | $3 | $1 | $7 | $6 | $3 | $1 |
| Total Operating Expenses | $6 | $4 | $11 | — | — | — |
| Operating Income | -$4 | -$3 | -$11 | -$15 | -$8 | -$4 |
| Non-Operating | ||||||
| Net Interest Expense | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Non-Operating Income (Expense) | $0 | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | — |
| Minority Interest | -$0 | -$0 | -$0 | -$0 | -$0 | $0 |
| Net Income | ||||||
| Net Income | -$4 | -$3 | -$12 | -$10 | -$4 | -$4 |
| Per Share Data | ||||||
| Revenue Per Share | $0.43 | $0.44 | $0.00 | — | — | — |
| EPS (Basic) | -$2.23 | -$0.93 | -$15.79 | -$73.48 | -$122.25 | -$247.50 |
| EPS (Diluted) | -$2.24 | -$0.91 | -$5.53 | -$30.40 | -$121.91 | -$247.50 |
| Weighted Avg Shares (Basic) | 3.3M | 3.1M | 1.3M | 10.6M | 2.2M | 17.0M |
| Weighted Avg Shares (Diluted) | — | — | — | — | 2.2M | 17.0M |
| Shares Outstanding | 3.3M | 3.2M | 2.1M | 341,301.627 | 29,135.453 | 15,108.946 |
Avenue Therapeutics (ATXI) financials: revenue, profit and margins
Avenue Therapeutics (ATXI) generated about n/a in revenue and -$3 million in net income (a -207.2% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Avenue Therapeutics profitable?+
Avenue Therapeutics reported about -$3 million in net loss over the trailing twelve months, a net margin of roughly -207.2%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Avenue Therapeutics's profit margins?+
Avenue Therapeutics runs an operating margin of about -219.6%, a net margin of about -207.2%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
SourceFinancial statements computed from the 10-Q filed 4 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 8 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.